|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:brand
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:CASNumber
|
gptkb:136817-59-9
|
|
gptkbp:commonName
|
gptkb:Sildenafil
|
|
gptkbp:contraindication
|
nitrates
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:halfLife
|
3-5 hours
|
|
gptkbp:hasMolecularFormula
|
C22H30N6O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
136817-59-9
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:IUPACName
|
gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:mechanismOfAction
|
PDE5 inhibitor
|
|
gptkbp:meltingPoint
|
189-190°C
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
474.58 g/mol
|
|
gptkbp:PubChem_CID
|
5212
CHEMBL192
DB00203
|
|
gptkbp:sideEffect
|
headache
nasal congestion
dyspepsia
flushing
visual disturbances
|
|
gptkbp:usedFor
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:bfsParent
|
gptkb:delavirdine
|
|
gptkbp:bfsLayer
|
6
|